Clinical trial for high tumour burden follicular lymphoma
ALLG clinical trial NHL30: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
Trial Lead: Associate Professor Judith Trotman.
NHL30 is an international Phase III trial.
The study aims to use a [18F]-Fluoro-deoxyglucose (FDG) PET-computed tomography (CT) response-adapted approach, with two randomisations aimed to improve the outcome of patients who remain PET-positive after initial immunochemotherapy, who have been demonstrated to have a very poor outcome, (a superiority study), and to minimise further treatment for good prognosis patients who become PET-negative (a non-inferiority study). In addition, a comprehensive set of correlative samples will be collected to define immunologic biomarkers of response to treatment.
The clinical trial will recruit approximately 37 patients across 6 Australasian sites. The timeline for the recruitment of patients is 2018 to 2023.
For more information on current clinical trials, visit the ALLG website.
Last updated on January 30th, 2023
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.